Summary & Overview

Medical Back Problems with Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 551 addresses inpatient admissions for medical back problems complicated by a Major Complication or Comorbidity; it encompasses cases where additional serious conditions increase resource needs. This Diagnosis-Related Group matters because the presence of a Major Complication or Comorbidity elevates the reimbursement level to account for greater intensity of care and longer hospitalization.

Medical Back Problems with MCCDRG Medical Back Problems with MCCDRG 551Diagnosis-Related GroupInpatient ReimbursementMedicareHospital MedicineSpine CareCoding and DocumentationReimbursement Policy

DRG 551 Overview

DRG 551 covers hospital admissions for medical back problems where a Major Complication or Comorbidity is present, such as severe systemic illness or significant organ dysfunction that complicates management. Typical clinical presentations include acute exacerbations of chronic back pain, spinal infection, or neurologic compromise requiring intensified medical management. This Diagnosis-Related Group influences Medicare payment by reflecting higher resource use and longer lengths of stay when a Major Complication or Comorbidity is documented. Accurate clinical documentation and coding of the Major Complication or Comorbidity are central to proper inpatient reimbursement.

National Payment Rates

Across commercial payers the observed rate range runs from about $15K (BCBS minimum) up to $57K (Anthem maximum), with mean payer averages clustered between $15K and $27K. The widest spread is seen with Anthem, where values span from as low as $390 to $57K. See the table and chart below for payer-specific percentiles and distributions.

Mean Rates by Payer — National — DRG 551

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($15.2k), average submitted covered charges ($74.4k), average Medicare payment amount ($12.7k), and total discharges (14.5k). These figures summarize payments and volumes at the national level for Medicare FFS beneficiaries.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 551 mean reimbursements span from $26K to $40K across payers, with Blue Cross Blue Shield and Anthem clustered at $26K and Cigna at $40K. The Cigna mean sits well above the other state payers and is a clear outlier versus local rates. Compared with national averages, Cigna’s Alaska mean is substantially higher while BCBS/Anthem are aligned below national payer means. See the table and chart below for the payer-level breakdown.

Key Insights for Alaska

Highest payer: Cigna (mean $40K); Lowest payers: Blue Cross Blue Shield and Anthem (both mean $26K).
Cigna’s mean reimbursement at $40K notably exceeds the other local payers and is meaningfully above national means for most payers, reflecting a higher regional rate for DRG 551 in Alaska.

Clinical Trials

Acute inpatient intervention trials evaluating multimodal pain control and early mobilization protocols for hospitalized patients with severe medical back problems complicated by major comorbid conditions (MCC), such as advanced cardiopulmonary disease or uncontrolled diabetes. These studies enroll medically complex, often older adults admitted for acute exacerbations of back pain or radiculopathy where comorbidities influence analgesic choices and mobility plans; outcomes measured include pain scores, opioid consumption, adverse events related to comorbidity interactions, and length of stay. Findings are relevant to providers for optimizing safe, effective inpatient care pathways and to payers for identifying protocols that reduce complications, readmissions, and resource use in a high-cost DRG population.
Comparative effectiveness trials comparing nonoperative inpatient therapies (e.g., targeted nerve interventions, image-guided injections, or structured physical therapy regimens) versus conservative medical management in patients with medical back problems who are poor surgical candidates due to MCC. These trials focus on subgroups with specific comorbid profiles—such as anticoagulation, chronic kidney disease, or severe cardiopulmonary illness—to determine which modalities yield the best functional recovery, pain reduction, and complication profiles during the index hospitalization and at short-term follow-up. The results inform clinicians on selecting interventions that balance efficacy and safety in complex patients and help payers evaluate which inpatient services provide the best value for this DRG.
Post-discharge outcomes and care coordination studies examining transitions from hospital to home or skilled nursing for patients with medical back problems and MCC, including interventions like comprehensive discharge planning, outpatient rehabilitation referral models, or remote monitoring to prevent readmission. These prospective cohort or pragmatic trials enroll patients with high comorbidity burden to assess 30- and 90-day readmissions, functional status, adherence to outpatient therapy, and total cost of care across settings. This research is crucial for providers and payers to identify strategies that improve long-term outcomes and reduce downstream utilization and costs associated with this medically complex DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$15K	$74K	$13K	14K

Acute inpatient intervention trials evaluating multimodal pain control and early mobilization protocols for hospitalized patients with severe medical back problems complicated by major comorbid conditions (MCC), such as advanced cardiopulmonary disease or uncontrolled diabetes. These studies enroll medically complex, often older adults admitted for acute exacerbations of back pain or radiculopathy where comorbidities influence analgesic choices and mobility plans; outcomes measured include pain scores, opioid consumption, adverse events related to comorbidity interactions, and length of stay. Findings are relevant to providers for optimizing safe, effective inpatient care pathways and to payers for identifying protocols that reduce complications, readmissions, and resource use in a high-cost DRG population.
Comparative effectiveness trials comparing nonoperative inpatient therapies (e.g., targeted nerve interventions, image-guided injections, or structured physical therapy regimens) versus conservative medical management in patients with medical back problems who are poor surgical candidates due to MCC. These trials focus on subgroups with specific comorbid profiles—such as anticoagulation, chronic kidney disease, or severe cardiopulmonary illness—to determine which modalities yield the best functional recovery, pain reduction, and complication profiles during the index hospitalization and at short-term follow-up. The results inform clinicians on selecting interventions that balance efficacy and safety in complex patients and help payers evaluate which inpatient services provide the best value for this DRG.
Post-discharge outcomes and care coordination studies examining transitions from hospital to home or skilled nursing for patients with medical back problems and MCC, including interventions like comprehensive discharge planning, outpatient rehabilitation referral models, or remote monitoring to prevent readmission. These prospective cohort or pragmatic trials enroll patients with high comorbidity burden to assess 30- and 90-day readmissions, functional status, adherence to outpatient therapy, and total cost of care across settings. This research is crucial for providers and payers to identify strategies that improve long-term outcomes and reduce downstream utilization and costs associated with this medically complex DRG.

OpenPayer

Summary & Overview

Medical Back Problems with Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 551 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes